| Reference |
|---|
Meneghetti B, Wilson R, Dias C, Cadore N, Klamt F, Zaha A, et al. p53 mutants G245S and R337H associated with the Li-Fraumeni syndrome regulate distinct metabolic pathways. Biochimie. 2022;198:141-154 pubmed publisher |
Gonzalez Rellan M, Fondevila M, Fernandez U, Rodríguez A, Varela Rey M, Veyrat Durebex C, et al. O-GlcNAcylated p53 in the liver modulates hepatic glucose production. Nat Commun. 2021;12:5068 pubmed publisher |
Palanikumar L, Karpauskaite L, Al Sayegh M, Chehade I, Alam M, Hassan S, et al. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Nat Commun. 2021;12:3962 pubmed publisher |
Saini H, Sharma H, Mukherjee S, Chowdhury S, Chowdhury R. Verteporfin disrupts multiple steps of autophagy and regulates p53 to sensitize osteosarcoma cells. Cancer Cell Int. 2021;21:52 pubmed publisher |
Kutle I, Szymańska de Wijs K, Bogdanow B, Cuvalo B, Steinbrück L, Jonjic S, et al. Murine Cytomegalovirus M25 Proteins Sequester the Tumor Suppressor Protein p53 in Nuclear Accumulations. J Virol. 2020;94: pubmed publisher |
Long J, Galvan D, Mise K, Kanwar Y, Li L, Poungvarin N, et al. Role for carbohydrate response element-binding protein (ChREBP) in high glucose-mediated repression of long noncoding RNA Tug1. J Biol Chem. 2020;: pubmed publisher |
Lim J, Choi J, Park E, Choi Y. Interaction of promyelocytic leukemia/p53 affects signal transducer and activator of transcription-3 activity in response to oncostatin M. Korean J Physiol Pharmacol. 2020;24:203-212 pubmed publisher |
Mancikova V, Peschelova H, Kozlova V, Ledererova A, Ladungova A, Verner J, et al. Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. J Immunother Cancer. 2020;8: pubmed publisher |
Xu Y, Xu Z, Li Q, Guo L, Wang Y, Zhou J, et al. Mutated p53 Promotes the Symmetric Self-Renewal of Cisplatin-Resistant Lung Cancer Stem-Like Cells and Inhibits the Recruitment of Macrophages. J Immunol Res. 2019;2019:7478538 pubmed publisher |
Lin S, Yu L, Song X, Bi J, Jiang L, Wang Y, et al. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death Dis. 2019;10:666 pubmed publisher |
Aggarwal M, Saxena R, Asif N, Sinclair E, Tan J, Cruz I, et al. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition. J Exp Clin Cancer Res. 2019;38:307 pubmed publisher |
Liu M, Wang Z, Liu Q, Zhu H, Xu N. Expression of Micro-RNA-492 (MiR-492) in Human Cervical Cancer Cell Lines is Upregulated by Transfection with Wild-Type P53, Irradiation, and 5-Fluorouracil Treatment In Vitro. Med Sci Monit. 2018;24:7750-7758 pubmed publisher |
Luff S, Kao C, Papoutsakis E. Role of p53 and transcription-independent p53-induced apoptosis in shear-stimulated megakaryocytic maturation, particle generation, and platelet biogenesis. PLoS ONE. 2018;13:e0203991 pubmed publisher |
Yang Hartwich Y, Tedja R, Roberts C, Goodner Bingham J, Cardenas C, Gurea M, et al. p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT. Mol Cancer Res. 2019;17:153-164 pubmed publisher |
Salari A, Thomay K, Lentes J, Ebersold J, Hagedorn M, Skawran B, et al. Effect of TP53 contact and conformational mutations on cell survival and erythropoiesis of human hematopoietic stem cells in a long term culture model. Oncotarget. 2018;9:29869-29876 pubmed publisher |
Mircetic J, Dietrich A, Paszkowski Rogacz M, Krause M, Buchholz F. Development of a genetic sensor that eliminates p53 deficient cells. Nat Commun. 2017;8:1463 pubmed publisher |
Mukherjee S, Dash S, Lohitesh K, Chowdhury R. The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cells. PLoS ONE. 2017;12:e0179203 pubmed publisher |
Ros S, Flöter J, Kaymak I, da Costa C, Houddane A, Dubuis S, et al. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells. Oncogene. 2017;36:3287-3299 pubmed publisher |
Karthikeyan S, Lantvit D, Chae D, Burdette J. Cadherin-6 type 2, K-cadherin (CDH6) is regulated by mutant p53 in the fallopian tube but is not expressed in the ovarian surface. Oncotarget. 2016;7:69871-69882 pubmed publisher |
Kitade S, Onoyama I, Kobayashi H, Yagi H, Yoshida S, Kato M, et al. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors. Cancer Sci. 2016;107:1399-1405 pubmed publisher |
Salari A, Thomay K, Himmler K, Vajen B, Schienke A, Hagedorn M, et al. Establishing a murine xenograft-model for long-term analysis of factors inducing chromosomal instability in myelodysplastic syndrome: Pitfalls and successes. Cancer Genet. 2016;209:258-66 pubmed publisher |
Ho D, Kim H, Kim J, Sim H, Ahn H, Kim J, et al. Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression. Mol Brain. 2015;8:54 pubmed publisher |
Escobar D, Hepp M, Farkas C, Campos T, Sodir N, Morales M, et al. Sall2 is required for proapoptotic Noxa expression and genotoxic stress-induced apoptosis by doxorubicin. Cell Death Dis. 2015;6:e1816 pubmed publisher |
Chung J, Larsen A, Chen E, Bunz F. A PTCH1 homolog transcriptionally activated by p53 suppresses Hedgehog signaling. J Biol Chem. 2014;289:33020-31 pubmed publisher |
O Hainmhire E, Quartuccio S, Cheng W, Ahmed R, King S, Burdette J. Mutation or loss of p53 differentially modifies TGF? action in ovarian cancer. PLoS ONE. 2014;9:e89553 pubmed publisher |
Ferreira D, Afonso M, Rodrigues P, Simão A, Pereira D, Borralho P, et al. c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. Mol Cell Biol. 2014;34:1100-20 pubmed publisher |
Sauer L, Gitenay D, Vo C, Baron V. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene. 2010;29:2628-37 pubmed publisher |
Baker S, Markowitz S, Fearon E, Willson J, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249:912-5 pubmed |
